Cancer therapeutics and diagnostics - MabCureAlternative Names: anti-PROSCA; anti-PROSCA monoclonal antibodies
Latest Information Update: 16 Apr 2012
At a glance
- Originator MabCure
- Class Antibody diagnostics; Diagnostic agents; Monoclonal antibodies; Monoclonal antibody diagnostics
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Ovarian cancer
- Preclinical Cancer
- Research Colorectal cancer; Malignant melanoma; Prostate cancer